| Trial ID: | L0977 |
| Source ID: | NCT00035178
|
| Associated Drug: |
Argatroban
|
| Title: |
Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Kidney Failure, Chronic|Renal Disease, End-Stage
|
| Interventions: |
DRUG: Argatroban
|
| Outcome Measures: |
|
| Sponsor/Collaborators: |
Sponsor: Texas Biotechnology Corporation
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
12
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: |Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2002-05
|
| Completion Date: |
2002-11
|
| Results First Posted: |
|
| Last Update Posted: |
2005-06-24
|
| Locations: |
University of Chicago, Section of Nephrology, Chicago, Illinois, 60637, United States|DaVita Clinical Research, Minneapolis, Minnesota, 55404, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00035178
|
